# A Study of HBM9161 in NMOSD Patients

> **NCT04227470** · PHASE1 · COMPLETED · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 9 (actual)

## Conditions studied

- NMO Spectrum Disorder

## Interventions

- **DRUG:** HBM9161 Injection

## Key facts

- **NCT ID:** NCT04227470
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-31
- **Primary completion:** 2021-12-03
- **Final completion:** 2021-12-24
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227470, "A Study of HBM9161 in NMOSD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04227470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*